Table 3 Summary of geometric mean antibody concentration (Per-Protocol Immunogenicity Population)
Antibody | Assessment | Lot A | Lot B | Lot C | |||
|---|---|---|---|---|---|---|---|
GMC | 95 % CI | GMC | 95 % CI | GMC | 95 % CI | ||
Diphtheria | Pre-dose 1 | 0.004 | 0.003–0.004 | 0.004 | 0.004–0.006 | 0.004 | 0.003–0.004 |
Post-dose 3 | 0.37 | 0.30–0.44 | 0.30 | 0.25–0.36 | 0.34 | 0.29–0.40 | |
Tetanus | Pre-dose 1 | 1.85 | 1.48–2.30 | 1.79 | 1.43–2.23 | 1.98 | 1.61–2.44 |
Post-dose 3 | 1.63 | 1.38–1.93 | 1.58 | 1.34–1.86 | 1.38 | 1.15–1.65 | |
Pertussis | Pre-dose 1 | 6.49 | 5.96–7.07 | 6.42 | 5.89–7.00 | 6.22 | 5.75–6.74 |
Post-dose 3 | 168.81 | 137.86–206.71 | 100.55 | 81.31–124.35 | 106.72 | 87.02–130.89 | |
Hepatitis B | Pre-dose 1 | 0.005 | 0.003–0.008 | 0.007 | 0.004–0.01 | 0.006 | 0.003–0.01 |
Post-dose 3 | 317.61 | 242.07–416.74 | 514.16 | 419.68–629.91 | 574.55 | 490.12–673.52 | |
PRP (Hib) | Pre-dose 1 | 0.008 | 0.005–0.01 | 0.005 | 0.003–0.007 | 0.007 | 0.005–0.01 |
Post-dose 3 | 22.13 | 18.32–26.73 | 17.72 | 14.50–21.65 | 20.32 | 16.50–25.03 | |